

Contact:  
Misha Plam  
AmideBio, LLC  
President & CEO  
[m.plam@comcast.net](mailto:m.plam@comcast.net)  
(303) 641-3669  
<http://www.AmideBio.com>

Contact:  
Lindsay Polak  
Marketing/Communications Manager  
University of Colorado Technology Transfer  
Office  
[Lindsay.polak@cu.edu](mailto:Lindsay.polak@cu.edu)  
(303) 735-5518  
<http://www.cu.edu/techtransfer>

## AmideBio Expands Alzheimer's Disease Partnership with University of Colorado

**Boulder, CO (PR Web) April 14, 2010** -- The University of Colorado and AmideBio, LLC have completed an agreement creating a research collaboration with a CU-Boulder lab, and giving AmideBio an option to newly-discovered drug candidates for Alzheimer's disease.

Alzheimer's disease is the most common cause of dementia in the U.S., and the fifth-leading cause of death for those aged 65 and older. An estimated 5.3 million Americans of all ages have Alzheimer's disease.<sup>1</sup> Alzheimer's disease typically begins with gradual memory loss; people with advanced Alzheimer's are often unable to perform basic activities such as dressing and eating without assistance. In the final stages, patients are unable to communicate or recognize family members, and require constant care. Alzheimer's disease is ultimately fatal, often by causing Alzheimer-related pneumonia.

Research under the new sponsored research agreement with the lab of Michael Stowell, Ph.D. (an associate professor of molecular, cellular and developmental biology) will use a novel screening process to find compounds that affect the interaction between two proteins believed to be involved in Alzheimer's disease. The agreement gives AmideBio an option to new compounds that are discovered using this screen, which Stowell believes will be useful in treating the disease. "AmideBio's commitment to our research will help to accelerate the discovery of potential therapeutics for Alzheimer's by providing both financial support and the large quantities of amyloid peptides needed for screening," said Stowell.

Earlier in 2010, AmideBio licensed a CU technology (also from the Stowell lab) for manufacturing recombinant proteins and peptides (molecules which are similar to proteins but smaller). These types of molecules are often key for treating diseases that cannot be addressed using conventional chemical therapeutics, but the field has historically been limited by challenges such as economical manufacturing and delivery. CU's technology circumvents these problems, particularly those associated with longer and more complex peptides, by leveraging a proprietary recombinant strategy that is economically viable and environmentally sustainable.

1. [2010 Alzheimer's Disease Facts and Figures](#). Alzheimer's Association, 2010.

# AmideBio



## **About AmideBio, LLC**

AmideBio based in Boulder, CO is a biotechnology company focused on providing recombinant peptide research and clinical products for a diverse array of disease research and disease targets. AmideBio maintains a proprietary platform vector technology that addresses the challenges of historically difficult to manufacture peptides by providing products that are reliable (BioPure™), economical and incorporate environmentally sustainable practices. For more information please visit <http://www.AmideBio.com>

## **About the Technology Transfer Office and the University of Colorado**

The CU Technology Transfer Office (TTO) pursues, protects, packages, and licenses to business the intellectual property generated from research at CU. The TTO provides assistance to faculty, staff, and students, as well as to businesses looking to license or invest in CU technology. For more information about technology transfer at CU, visit [www.cu.edu/techtransfer](http://www.cu.edu/techtransfer).

The University of Colorado is a premier teaching and research university with four campuses: the University of Colorado at Boulder, the University of Colorado at Colorado Springs, the University of Colorado Denver and the University of Colorado Anschutz Medical Campus. More than 55,000 undergraduate and graduate students are pursuing academic degrees on CU campuses. CU is ranked seventh among public institutions in federal research expenditures in engineering and science by the National Science Foundation. Academic prestige is marked by the university's four Nobel laureates, seven MacArthur "genius" Fellows, 18 alumni astronauts and 19 Rhodes Scholars. For more information, go to [www.cu.edu](http://www.cu.edu).

###